ASIT.BR
ASIT Biotech S.A. [ASIT.BR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ASIT.BR Stock Summary
In the News
ASIT.BR Financial details
Company Rating
Neutral
Market Cap
0
Income
-15.48M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
30 Sep 2020
P/E
-2.69
Forward P/E
-
PEG
-
P/S
-
P/B
-0.89
P/C
-
P/FCF
-
Quick Ratio
0.28
Current Ratio
0.3
Debt / Equity
-0.93
LT Debt / Equity
-
-
-
EPS (TTM)
-0.78
EPS next Y
-
EPS next Q
-
EPS this Y
-89.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-36%
ROE
38%
ROC
0.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.229-0.235
52W High
-
52W Low
-
RSI
-
Rel Volume
0.45
Avg Volume
46.33K
Volume
20.68K
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.33101
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.229
Change
-
ASIT.BR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.1 | -0.94 | -0.86 | -0.78 | -0.09 | |
| Operating cash flow per share | -1.22 | -1 | -0.78 | -0.64 | -0.06 | |
| Free cash flow per share | -1.25 | -1.01 | -0.8 | -0.64 | -0.06 | |
| Cash per share | 1.19 | 0.17 | 0.51 | 0.18 | 0.13 | |
| Book value per share | 1.17 | 0.09 | 0.39 | -0.21 | -0.26 | |
| Tangible book value per share | 1.17 | 0.09 | 0.39 | -0.21 | -0.26 | |
| Share holders equity per share | 1.17 | 0.09 | 0.39 | -0.21 | -0.26 | |
| Interest debt per share | 0.05 | 0.04 | 0.13 | 0.25 | 0.26 | |
| Market cap | 2.57M | 2.93M | 3.83M | 4.66M | 5.01M | |
| Enterprise value | -10.39M | 1.27M | -2.52M | 5.94M | 7.45M | |
| P/E ratio | -0.21 | -0.24 | -0.27 | -0.29 | -2.69 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.19 | -0.23 | -0.29 | -0.36 | -3.64 | |
| PFCF ratio | -0.18 | -0.23 | -0.29 | -0.36 | -3.64 | |
| P/B Ratio | 0.2 | 2.45 | 0.59 | -1.12 | -0.89 | |
| PTB ratio | 0.2 | 2.45 | 0.59 | -1.12 | -0.89 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.86 | -0.11 | 0.18 | -0.39 | -10.91 | |
| EV to operating cash flow | 0.76 | -0.1 | 0.19 | -0.46 | -5.41 | |
| EV to free cash flow | 0.74 | -0.1 | 0.19 | -0.45 | -5.41 | |
| Earnings yield | -4.8 | -4.09 | -3.74 | -3.4 | -0.37 | |
| Free cash flow yield | -5.48 | -4.43 | -3.5 | -2.8 | -0.27 | |
| Debt to equity | 0.03 | 0.39 | 0.33 | -1.18 | -0.94 | |
| Debt to assets | 0.03 | 0.11 | 0.18 | 0.72 | 1.03 | |
| Net debt to EBITDA | 1.07 | 0.14 | 0.45 | -0.08 | -3.57 | |
| Current ratio | 6.88 | 0.92 | 1.98 | 0.39 | 0.3 | |
| Interest coverage | -133.11 | 0 | 0 | -74.27 | -1.71 | |
| Income quality | 1.11 | 1.07 | 0.91 | 0.83 | 1.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.03 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2.72 | -0.79 | -1.47 | -0.28 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.38 | 1.4 | 2.73 | 1.9 | 0.7 | |
| ROIC | -0.9 | -7.2 | -1.67 | -18.97 | 3.43 | |
| Return on tangible assets | -0.79 | -2.8 | -1.24 | -2.33 | -0.36 | |
| Graham Net | 0.98 | -0.07 | 0.2 | -0.36 | -0.36 | |
| Working capital | 11.78M | -206K | 4.54M | -6.45M | -7.28M | |
| Tangible asset value | 13.13M | 1.2M | 6.47M | -4.18M | -5.64M | |
| Net current asset value | 11.36M | -638K | 4.07M | -6.89M | -7.68M | |
| Invested capital | 0.03 | 0.39 | 0.33 | -1.18 | -0.94 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 680K | 809K | 924K | 2.25M | 3.71M | |
| Average inventory | 5.5K | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 458.08K | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.94 | -10 | -2.21 | 3.8 | 0.33 | |
| Capex per share | -0.03 | -0.01 | -0.02 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2019-06-30 | 2019-12-31 | 2020-06-30 | 2020-12-31 | 2021-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.19 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | -0.16 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | -0.16 | 0 | 0 | 0 | 0 | |
| Cash per share | 0.12 | 0 | 0 | 0 | 0 | |
| Book value per share | 0.08 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0.08 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0.08 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0.07 | 0 | 0 | 0 | 0 | |
| Market cap | 4.66M | 0 | 0 | 0 | 0 | |
| Enterprise value | 3.49M | 1.28M | 2.54M | 2.44M | 2.64M | |
| P/E ratio | -0.29 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.44 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -1.43 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 2.96 | 0 | 0 | 0 | 0 | |
| PTB ratio | 2.96 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -0.92 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | -1.08 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -1.07 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.85 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | -0.7 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.82 | -1.18 | -0.98 | -0.94 | -0.93 | |
| Debt to assets | 0.22 | 0.72 | 0.96 | 1.03 | 1.1 | |
| Net debt to EBITDA | 0.31 | 0 | 0 | 0 | 0 | |
| Current ratio | 0.9 | 0.39 | 0.31 | 0.3 | 0.28 | |
| Interest coverage | -74.27 | 0 | 0 | 0 | 0 | |
| Income quality | 0.83 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.28 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.58 | 0 | 0 | 0 | 0 | |
| ROIC | -1.32 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | -0.67 | 0 | 0 | 0 | 0 | |
| Graham Net | -0.09 | 0 | 0 | 0 | 0 | |
| Working capital | -374K | -6.45M | -7.4M | -7.28M | -7.54M | |
| Tangible asset value | 1.58M | -4.18M | -5.49M | -5.64M | -5.73M | |
| Net current asset value | -1.01M | -6.89M | -7.84M | -7.68M | -7.67M | |
| Invested capital | 0.82 | -1.18 | -0.98 | -0.94 | -0.93 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -2.52 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ASIT.BR Frequently Asked Questions
What is ASIT Biotech S.A. stock symbol ?
ASIT Biotech S.A. is a BE stock , located in Liege of Liege and trading under the symbol ASIT.BR
What is ASIT Biotech S.A. stock quote today ?
ASIT Biotech S.A. stock price is $0.229 today.
Is ASIT Biotech S.A. stock public?
Yes, ASIT Biotech S.A. is a publicly traded company.
Company Profile
- Volume Average 46.33K
- Employee 20
- CEO Mr. Thierry Legon
- Headquarters Liege,LIEGE,BE
- IPO Date 2016-05-11
-
Website
https://www.asitbiotech.com 
ASIT Biotech S.A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S.A. was incorporated in 1997 and is based in Liege, Belgium.
